RH3B Antibody

How do I select the appropriate antibody for ErbB3/Her3 detection in different experimental contexts?

When selecting an antibody for ErbB3/Her3 detection, consider the specific domain you aim to target (extracellular vs. intracellular) and whether post-translational modifications might affect epitope accessibility. For instance, ErbB3/Her3 contains multiple glycosylation sites in its extracellular domain that may interfere with antibody binding. Additionally, determine whether you need to detect native protein (suitable for immunoprecipitation or flow cytometry) or denatured protein (suitable for Western blotting). Based on available research data, monoclonal antibodies like the clone #526922 demonstrate high specificity for human ErbB3, detecting it at approximately 185 kDa under reducing conditions in breast cancer cell lines such as MDA-MB-453 and MCF-7 . Always perform validation using positive control lysates where ErbB3 is known to be expressed and negative controls where it is absent or knocked down.

How can I troubleshoot non-specific banding patterns when using ErbB3/Her3 antibodies in Western blot applications?

Non-specific bands in ErbB3/Her3 Western blots may arise from several sources. First, verify you're using the optimal antibody dilution; the literature indicates that 1 μg/mL of Human ErbB3/Her3 Monoclonal Antibody (MAB3482) has been optimized for Western blotting . To reduce background, incorporate extended blocking steps (2-3 hours at room temperature or overnight at 4°C) with 5% BSA rather than milk when detecting phosphorylated ErbB3. Ensure your gel percentage is appropriate for resolving high molecular weight proteins (~185 kDa for ErbB3) . Including protease and phosphatase inhibitors in your lysis buffer prevents degradation products that appear as lower molecular weight bands. If multiple bands persist around the expected molecular weight, consider whether different isoforms, post-translational modifications, or proteolytic processing might be occurring. Finally, validate specificity by including lysates from ErbB3 knockout cells, which should eliminate specific bands.

What techniques can detect changes in Rheb ubiquitination status in response to amino acid availability?

Detecting changes in Rheb ubiquitination requires multiple complementary approaches. The most direct method involves immunoprecipitating endogenous Rheb followed by immunoblotting with anti-ubiquitin antibodies. Research has demonstrated that high molecular weight (HMW) Rheb species can be detected after immunoprecipitation and represent polyubiquitinated forms . To confirm these are ubiquitinated species, treat cells with proteasome inhibitors like MG-132, which causes accumulation of polyubiquitinated proteins. Additionally, co-expressing HA-tagged ubiquitin followed by Rheb immunoprecipitation and anti-HA blotting can verify incorporation of ubiquitin into Rheb . To distinguish between different ubiquitin chain linkages, use linkage-specific antibodies (K48 vs. K63) or express ubiquitin mutants where specific lysines are mutated to arginine (e.g., K0 mutant) . For studying amino acid-dependent ubiquitination, compare cells under amino acid starvation versus replenishment conditions, as amino acid stimulation enhances Rheb polyubiquitination .

How can I assess the functional significance of ErbB3/Her3 in cancer models that express multiple ErbB family members?

Assessing ErbB3/Her3 functional significance in complex cancer models requires multi-level approaches. Begin with selective inhibition of ErbB3 using domain-specific antibodies that block ligand binding or heterodimerization with other ErbB receptors. Unlike other ErbB family members, ErbB3 contains a defective kinase domain but heterodimerizes with ErbB2 to form a high-affinity receptor complex with active signaling capability . To distinguish the contribution of ErbB3 from other family members, use CRISPR/Cas9 to create ErbB3 knockout models while preserving other ErbB receptors. Alternatively, employ siRNA/shRNA approaches for transient knockdown. Assess changes in downstream signaling, particularly through the PI3K pathway, as ErbB3 contains six consensus binding motifs for the SH2 domain of the p85 regulatory subunit of PI3K . Combine these approaches with functional assays measuring proliferation, migration, and resistance to therapeutic agents. Finally, perform rescue experiments by reintroducing wild-type ErbB3 or mutant variants to determine which domains are critical for the observed phenotypes.

What are the most effective methods for analyzing the interaction dynamics between Rheb and mTORC1 at the lysosomal membrane?

Analyzing Rheb-mTORC1 interaction dynamics at the lysosomal membrane requires techniques with high spatial and temporal resolution. Live-cell imaging using fluorescently tagged Rheb and mTOR components can track their colocalization in response to stimuli like amino acids. For higher resolution, use super-resolution microscopy techniques like STORM or PALM. Biochemically, lysosomal fractionation followed by co-immunoprecipitation can isolate lysosome-specific interactions . Recent research has demonstrated that polyubiquitinated Rheb (Ub-Rheb) shows stronger binding affinity for mTORC1 than non-ubiquitinated Rheb, particularly in response to amino acid stimulation . To manipulate this system, use lysosome-targeted constructs (like Lyso-ATXN3) to specifically modulate Rheb ubiquitination at the lysosomal surface . Proximity ligation assays can detect protein-protein interactions with spatial context, while FRET/BRET approaches measure real-time interaction dynamics. For perturbation studies, employ Rag GTPase mutants (active or inactive) to alter the amino acid sensing machinery, as research has shown that inactive Rag heterodimers recruit deubiquitinases like ATXN3 to the lysosome, reducing Rheb ubiquitination and mTORC1 activation .

How can computational tools improve antibody design for targeting specific ErbB3/Her3 epitopes?

Computational tools have revolutionized antibody design for targeting specific ErbB3/Her3 epitopes. Structure prediction algorithms like H3-OPT, which combines AlphaFold2 with protein language models, can accurately predict the complementarity determining region heavy chain 3 (CDR-H3) loop structures with an average RMSD of 2.24 Å . This precision is crucial since CDR-H3 loops form the most variable region of antibodies and often determine binding specificity. Begin by identifying conserved versus variable regions in the ErbB3 structure to select appropriate epitopes. For extracellular domain targeting, focus on regions that distinguish ErbB3 from other family members. Once target epitopes are identified, in silico antibody design can generate candidates, followed by computational docking to predict binding affinity and specificity. Molecular dynamics simulations can further refine these predictions by sampling conformational space and identifying stable binding modes . Models with favorable energetics can be selected for experimental validation. This integrated approach significantly reduces the time and resources required for antibody development while increasing the likelihood of generating high-affinity, specific antibodies against challenging ErbB3 epitopes.

What methodologies can assess the structural impact of antibody binding on ErbB3/Her3 dimerization and activation?

Assessing how antibody binding affects ErbB3/Her3 dimerization and activation requires both computational and experimental approaches. Structurally, hydrogen-deuterium exchange mass spectrometry (HDX-MS) can identify conformational changes induced by antibody binding. For direct visualization, single-particle cryo-electron microscopy can capture ErbB3-antibody complexes in different states. Functionally, bioluminescence resonance energy transfer (BRET) assays can measure dimerization dynamics in living cells before and after antibody treatment. Since ErbB3 lacks intrinsic kinase activity and relies on heterodimerization with ErbB2 for signaling , phosphorylation assays measuring activation of downstream pathways (particularly PI3K/AKT) provide functional readouts of inhibition. Surface plasmon resonance can determine binding kinetics and affinities of antibodies to monomeric versus dimeric receptor conformations. Recent developments in computational modeling using tools like H3-OPT can predict how antibodies interact with specific ErbB3 domains , while molecular dynamics simulations can reveal how these interactions might disrupt dimerization interfaces. To directly measure receptor proximity, chemical crosslinking followed by immunoprecipitation and mass spectrometry can map interaction interfaces in the presence or absence of antibodies.

How do I interpret and validate computational predictions of antibody-antigen interactions for rational antibody engineering?

Interpreting and validating computational predictions requires a systematic approach. Begin by assessing the confidence metrics provided by prediction algorithms—H3-OPT provides confidence scores that correlate with prediction accuracy, with higher confidence predictions (average RMSD of 2.24 Å) being more reliable than lower confidence ones . Compare multiple models generated by different algorithms (AlphaFold2, RosettaAntibody, etc.) and look for structural consensus. Examine predicted binding interfaces for physicochemical complementarity, hydrogen bonding networks, and shape matching. Validate computational predictions experimentally through site-directed mutagenesis of predicted key residues in both antibody and antigen, followed by binding assays to measure affinity changes. Epitope mapping using techniques like hydrogen-deuterium exchange mass spectrometry or peptide arrays can confirm predicted interaction sites. For quantitative validation, compare predicted binding energies with experimental measurements from isothermal titration calorimetry or surface plasmon resonance. Research has shown that quantum mechanics (QM)-based approaches can further refine antibody models, particularly for challenging CDR-H3 loops, with energy-based re-ranking methods achieving an average RMSD improvement of 0.69 Å for select targets . Finally, molecular dynamics simulations can explore conformational flexibility and identify stable conformations that may not be evident in static models.

How can I distinguish between ubiquitinated and non-ubiquitinated forms of Rheb in complex cell lysates?

Distinguishing between ubiquitinated and non-ubiquitinated Rheb forms requires specialized techniques. Western blotting typically reveals ubiquitinated Rheb (Ub-Rheb) as higher molecular weight bands above the main Rheb band. Research has confirmed these are ubiquitinated species by showing their accumulation after proteasome inhibition with MG-132 and incorporation of HA-tagged ubiquitin . For definitive identification, perform immunoprecipitation of endogenous Rheb followed by immunoblotting for both Rheb and ubiquitin. Ubiquitinated species can be further validated by expressing the ubiquitin K0 mutant (all lysines replaced with arginines), which significantly reduces high molecular weight Rheb forms . To distinguish between different ubiquitin chain types, use ubiquitin linkage-specific antibodies (K48, K63, etc.). For analyzing complex lysates, consider using tandem ubiquitin binding entities (TUBEs) to enrich all ubiquitinated proteins before Rheb immunoprecipitation. Additionally, mass spectrometry analysis of immunoprecipitated Rheb can identify specific ubiquitination sites and quantify ubiquitination levels. When comparing conditions like amino acid starvation versus stimulation, normalize your detection of ubiquitinated Rheb to total Rheb levels to account for expression differences.

What strategies help resolve contradictory results when studying ErbB3/Her3 activation using different antibodies?

Resolving contradictory results from different ErbB3/Her3 antibodies requires systematic troubleshooting. First, characterize each antibody's epitope location—antibodies targeting different domains may yield different results if conformational changes mask certain epitopes. ErbB3 undergoes significant conformational rearrangement during heterodimerization with other ErbB family members , potentially affecting epitope accessibility. Compare phospho-specific versus total protein antibodies, as they measure different aspects of receptor biology. Validate each antibody using positive and negative controls, including ErbB3 knockout or knockdown samples. If contradictions persist between immunoblotting and immunostaining results, consider whether fixation or denaturation affects epitope recognition. For activity assays, remember that ErbB3 contains a defective kinase domain and relies on heterodimerization with ErbB2 for signaling , so detection of activation may require measuring both ErbB3 phosphorylation and downstream pathway activation (particularly PI3K/AKT, as ErbB3 contains six PI3K binding motifs) . Finally, combine multiple detection methods (e.g., Western blot, immunofluorescence, ELISA) and multiple antibodies targeting different epitopes to build a consensus view of ErbB3 biology in your system.

How should I analyze data from molecular dynamics simulations to improve antibody structure predictions?

Analyzing molecular dynamics (MD) simulation data for antibody structure prediction requires a structured approach. Begin by calculating root-mean-square deviation (RMSD) values between your simulated structures and template or predicted structures, focusing particularly on the CDR-H3 loop region. Research has shown that MD simulations can generate conformations with significantly lower CDR-H3 Cα-RMSDs compared to initial AlphaFold2 predictions, with improvements of up to 5.30 Å observed in challenging cases like the 7N0R single-domain antibody . Assess conformational stability by examining root-mean-square fluctuation (RMSF) values for each residue—higher RMSF values indicate greater flexibility, with CDR-H3 loops typically showing greater fluctuation than framework regions . Perform cluster analysis to identify representative conformations from your trajectory, selecting the most populated clusters for further analysis. Calculate protein-protein interaction energies between the antibody and antigen across different conformational states to identify energetically favorable binding modes. Apply principal component analysis (PCA) to identify dominant motions and conformational states. For validation, compare your MD-refined models against experimental structures using metrics beyond RMSD, such as GDT-TS (Global Distance Test) scores, which better account for local structural quality. Finally, integrate MD results with experimental data such as hydrogen-deuterium exchange or epitope mapping to validate your structural predictions.

How can I use antibodies to study the dynamics of ErbB3/Her3 trafficking between cellular compartments?

Studying ErbB3/Her3 trafficking dynamics requires spatiotemporal resolution techniques. Develop a pulse-chase immunofluorescence approach using primary antibodies against extracellular ErbB3 epitopes applied to live cells at 4°C (to prevent internalization), followed by warming to 37°C to initiate trafficking. At various time points, fix cells and use compartment-specific markers (Rab5 for early endosomes, Rab7 for late endosomes, LAMP1 for lysosomes) to track receptor localization through the endocytic pathway. For live imaging, use pH-sensitive fluorophore-conjugated antibodies that change fluorescence intensity when transitioning between neutral (cell surface) and acidic (endosomal) environments. Alternatively, use split-GFP complementation systems where one fragment is fused to ErbB3 and the complementary fragment is targeted to specific compartments. For biochemical quantification, use surface biotinylation followed by streptavidin pull-down at various chase times to measure internalization rates. Cell surface ErbB3 levels can be quantified by flow cytometry using non-permeabilizing conditions. For studying recycling versus degradation fates, use cycloheximide to block new protein synthesis, allowing you to track the destiny of existing receptor pools. Remember that ligand binding and dimerization state significantly affect trafficking patterns, so compare ligand-stimulated versus basal conditions.

What approaches can investigate how deubiquitinases like ATXN3 regulate the mTOR pathway through Rheb modification?

Investigating deubiquitinase regulation of Rheb requires targeted approaches. To study ATXN3's role, employ both gain-of-function (overexpression) and loss-of-function (CRISPR knockout, shRNA knockdown) experiments. Research has shown that ATXN3 overexpression decreases Rheb ubiquitination, while its ablation using distinct sgRNAs increases ubiquitinated Rheb levels . For mechanistic studies, use subcellular targeting constructs like Lyso-ATXN3, which constitutively localizes to lysosomes and more effectively deubiquitinates Rheb than wild-type ATXN3 . To assess the dynamic regulation by amino acids, compare amino acid starvation versus replenishment conditions, as amino acid stimulation decreases lysosomal ATXN3 localization and its interaction with Rheb . Investigate the role of Rag GTPases in this process, as inactive Rag heterodimers strengthen ATXN3's interaction with Rheb, while active Rag heterodimers diminish it . For biochemical characterization, perform in vitro deubiquitination assays using purified components. Use proximity ligation assays to visualize the spatial relationship between ATXN3, Rheb, and mTORC1 components under different nutritional conditions. To connect these molecular events to functional outcomes, measure mTORC1 substrate phosphorylation (e.g., S6K, 4E-BP1) and cellular processes like autophagy and protein synthesis in response to manipulation of the ATXN3-Rheb axis.

How can combining antibody-based detection with computational modeling advance our understanding of receptor tyrosine kinase signaling networks?

Integrating antibody-based detection with computational modeling creates powerful synergies for studying receptor tyrosine kinase networks. Begin by collecting quantitative data using multiplexed antibody approaches that simultaneously measure multiple network components—phospho-specific antibody arrays can profile activation states across the ErbB signaling network, while mass cytometry (CyTOF) provides single-cell resolution of dozens of signaling nodes. Feed this experimental data into computational models that capture network topology and dynamics. For ErbB3, which contains six PI3K binding motifs and forms heterodimers with other ErbB receptors , computational models can predict how different dimerization patterns influence downstream pathway activation. Iteratively refine these models by experimentally testing their predictions using targeted antibodies against key nodes. Advanced structural modeling tools like H3-OPT can predict antibody-antigen interactions at the molecular level, informing the design of antibodies that selectively disrupt specific protein-protein interfaces within the network. This approach is particularly valuable for studying ErbB3, where heterodimerization with ErbB2 is critical for signaling despite ErbB3's defective kinase domain . Time-course experiments using these antibodies can reveal network dynamics, while perturbation experiments (e.g., inhibitor treatment, gene knockdown) test model predictions about network robustness and adaptation. Finally, integrate multi-omics data (phosphoproteomics, transcriptomics) with computational network models to understand system-wide responses to targeted interventions.